Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Hum Mol Genet ; 32(9): 1552-1564, 2023 04 20.
Article in English | MEDLINE | ID: mdl-36611016

ABSTRACT

Congenital myasthenic syndrome (CMS) is a heterogeneous condition associated with 34 different genes, including SLC5A7, which encodes the high-affinity choline transporter 1 (CHT1). CHT1 is expressed in presynaptic neurons of the neuromuscular junction where it uses the inward sodium gradient to reuptake choline. Biallelic CHT1 mutations often lead to neonatal lethality, and less commonly to non-lethal motor weakness and developmental delays. Here, we report detailed biochemical characterization of two novel mutations in CHT1, p.I294T and p.D349N, which we identified in an 11-year-old patient with a history of neonatal respiratory distress, and subsequent hypotonia and global developmental delay. Heterologous expression of each CHT1 mutant in human embryonic kidney cells showed two different mechanisms of reduced protein function. The p.I294T CHT1 mutant transporter function was detectable, but its abundance and half-life were significantly reduced. In contrast, the p.D349N CHT1 mutant was abundantly expressed at the cell membrane, but transporter function was absent. The residual function of the p.I294T CHT1 mutant may explain the non-lethal form of CMS in this patient, and the divergent mechanisms of reduced CHT1 function that we identified may guide future functional studies of the CHT1 myasthenic syndrome. Based on these in vitro studies that provided a diagnosis, treatment with cholinesterase inhibitor together with physical and occupational therapy significantly improved the patient's strength and quality of life.


Subject(s)
Mutant Proteins , Mutation , Myasthenic Syndromes, Congenital , Symporters , Myasthenic Syndromes, Congenital/drug therapy , Myasthenic Syndromes, Congenital/genetics , Myasthenic Syndromes, Congenital/metabolism , Myasthenic Syndromes, Congenital/rehabilitation , Humans , Male , Child , HEK293 Cells , Mutant Proteins/chemistry , Mutant Proteins/genetics , Mutant Proteins/metabolism , Half-Life , Cell Membrane/metabolism , Protein Transport , Staurosporine/pharmacology , Pyridostigmine Bromide/therapeutic use , Quality of Life , Symporters/chemistry , Symporters/genetics , Symporters/metabolism
2.
Sci Rep ; 9(1): 3099, 2019 02 28.
Article in English | MEDLINE | ID: mdl-30816203

ABSTRACT

In the renal collecting duct, intercalated cells regulate acid-base balance by effluxing protons through the v-H+-ATPase, and bicarbonate via apical pendrin or the basolateral kidney anion exchanger 1 (kAE1). Additionally, collecting duct cells play an essential role in transepithelial absorption of sodium and chloride. Expression of kAE1 in polarized MDCK I cells was previously shown to decrease trans-epithelial electrical resistance (TEER), suggesting a novel role for kAE1 in paracellular permeability. In our study, we not only confirmed that inducible expression of kAE1 in mIMCD3 cells decreased TEER but we also observed (i) increased epithelial absolute permeability to both sodium and chloride, and (ii) that this effect was dependent on kAE1 activity. Further, kAE1 regulated tight junction properties through the tight junction protein claudin-4, a protein with which it physically interacts and colocalizes. These findings unveil a novel interaction between the junctional protein claudin-4 and the kidney anion exchanger, which may be relevant to ion and/or pH homeostasis.


Subject(s)
Anion Exchange Protein 1, Erythrocyte/physiology , Claudin-4/metabolism , Kidney Tubules, Collecting/cytology , Tight Junctions/metabolism , Animals , Biological Transport , Cell Line , Cell Membrane Permeability , Chlorides/metabolism , Electric Impedance , Kidney/metabolism , Mice , Sodium/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...